BML reports 9.9% stake in PMV Pharmaceuticals
BML Investment Partners, L.P. filed an amended Schedule 13G reporting its ownership in PMV Pharmaceuticals, Inc..
Rhea-AI Filing Summary
BML Investment Partners, L.P. filed an amended Schedule 13G reporting its ownership in PMV Pharmaceuticals, Inc.. The fund reports beneficial ownership of 5,292,000 shares of common stock, representing 9.9% of the class as of the event date.
BML has shared voting and dispositive power over all 5,292,000 shares and no sole voting or dispositive power. The filing notes that the securities are not held for the purpose of changing or influencing control of PMV Pharmaceuticals. Braden M. Leonard is deemed an indirect owner through BML Capital Management, LLC, the general partner.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in PMV Pharmaceuticals (PMVP) does BML Investment Partners report?
What type of SEC filing did BML submit for PMV Pharmaceuticals (PMVP)?
Does BML Investment Partners seek to influence control of PMV Pharmaceuticals (PMVP)?
Who signs the PMV Pharmaceuticals (PMVP) Schedule 13G/A for BML Investment Partners?
What percentage threshold does BML Investment Partners exceed in PMV Pharmaceuticals (PMVP)?
Do the reporting persons claim to be a group in the PMV Pharmaceuticals (PMVP) filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.